#United States #Pleasanton, California #10x Genomics #Scale Biosciences #single cell analysis

10x Genomics' Strategic Move

In a significant development in the field of biotechnology, 10x Genomics, Inc. (Nasdaq: TXG), a prominent player in single cell and spatial biology, has officially announced its decision to acquire Scale Biosciences, Inc. This strategic acquisition is poised to greatly enhance 10x's existing capabilities and position it as a more formidable leader in the innovative landscape of single cell analysis.

Integration of Technology for Broader Access

The agreement, finalized on August 7, 2025, is set to bring Scale's groundbreaking technologies into the 10x ecosystem, notably its achievements in scalable single cell analysis through distinct methodologies such as combinatorial indexing and quantum barcoding. These innovations represent a significant leap in making single cell analysis not just more efficient but also immensely more accessible to researchers worldwide.

Garry Nolan, a co-founder of Scale Biosciences and a Stanford University professor, remarked that these cutting-edge technologies were conceived to revolutionize single cell analysis, making it more scalable and approachable. Joining 10x as advisors, Nolan along with fellow scientists Jay Shendure and Cole Trapnell, aims to further expedite the integration of these technologies into the 10x framework, driving a wave of innovation that could transform biological research.

10x Genomics' Vision for the Future

Serge Saxonov, CEO of 10x Genomics, expressed excitement about the acquisition, underscoring the company's relentless drive to democratize access to advanced single cell technologies. The integration of Scale’s innovations with its own platform is believed to forge new pathways for current and future products while extending their reach within the scientific community. Saxonov highlighted that this move reflects the commitment of 10x to accelerate the adoption of single cell technologies, making them more routine and practical for various research applications.

Supporting Scientific Advancement

Following the integration, 10x Genomics is keen to support existing Scale customers while also initiating ambitious projects such as the 100 Million Cell Challenge and the Billion Cells Project. These initiatives align with 10x's mission to enhance the quality and breadth of single cell analyses, ensuring that valuable data remains accessible and useful for the scientific community.

Giovanna Prout, President and CEO of Scale Bio, lauded the partnership, acknowledging the potential for their technologies to reach a broader customer base, thus propelling an enhanced understanding of biology.

The acquisition is anticipated to facilitate a robust product roadmap focused on single cell innovation. By enhancing the number of cells and samples that researchers can analyze, the quality of data generated will support AI-driven breakthroughs in fields like oncology, immunology, and neuroscience.

Conclusion

The acquisition of Scale Biosciences by 10x Genomics marks a pivotal moment in the evolution of biological study. As the landscape of biotechnology continues to evolve, so too does the commitment of leaders in the field to empower researchers with enhanced tools and technologies. 10x Genomics is set to not only maintain Scale's market presence but also to expand the profound impact these innovations can have on scientific discovery and human health. This merger promises to drive the next wave of breakthroughs in single cell biology, creating pathways for a future laden with potential.

For more information about 10x Genomics and their innovative solutions in single cell analysis, visit their website or follow them on social media channels such as LinkedIn and X.